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Syndrome of Reversible Cardiogenic
Shock and Left Ventricular Ballooning in
Obstructive Hypertrophic Cardiomyopathy
Mark V. Sherrid , MD; Daniel G. Swistel, MD; Iacopo Olivotto , MD; Maurizio Pieroni , MD;
Omar Wever-Pinzon , MD; Katherine Riedy, MD; Richard G. Bach, MD; Mustafa Husaini , MD;
Sharon Cresci , MD; Alex Reyentovich, MD; Daniele Massera , MD; Martin S. Maron, MD;
Barry J. Maron, MD; Bette Kim, MD
BACKGROUND: Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can
uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left
ventricular (LV) outflow obstruction. Typical HCM phenotypic features of mild septal thickening, outflow gradients, and distinctive mitral abnormalities differentiate these patients from others with Takotsubo syndrome, who have normal mitral valves and
no outflow obstruction.

Downloaded from http://ahajournals.org by on December 14, 2021

METHODS AND RESULTS: We analyzed 8 patients from our 4 HCM centers with obstructive HCM and abrupt presentation of cardiogenic shock with LV ballooning, and 6 cases reported in literature. Of 14 patients, 10 (71%) were women, aged 66±9 years, presenting with acute symptoms: LV ballooning; depressed ejection fraction (25±5%); refractory systemic hypotension; marked LV outflow
tract obstruction (peak gradient, 94±28 mm Hg); and elevated troponin, but absence of atherosclerotic coronary disease. Shock
was managed with intravenous administration of phenylephrine (n=6), norepinephrine (n=6), β-blocker (n=7), and vasopressin (n=1).
Mechanical circulatory support was required in 8, including intra-aortic balloon pump (n=4), venoarterial extracorporeal membrane
oxygenation (n=3), and Impella and Tandem Heart in 1 each. In refractory shock, urgent relief of obstruction by myectomy was
performed in 5, and alcohol ablation in 1. All patients survived their critical illness, with full recovery of systolic function.
CONCLUSIONS: When cardiogenic shock and LV ballooning occur in obstructive HCM, they are marked by distinctive anatomic
and physiologic features. Relief of obstruction with targeted pharmacotherapy, mechanical circulatory support, and myectomy, when necessary for refractory shock, may lead to survival and normalization of systolic function.
Key Words: cardiogenic shock ■ hypertrophic cardiomyopathy ■ hypertrophic obstructive cardiomyopathy ■ left ventricular ballooning

■ left ventricular outflow tract obstruction ■ supply-demand ischemia ■ Takotsubo syndrome

T

he course of obstructive hypertrophic cardiomyopathy (HCM) can uncommonly but dramatically
be punctuated by an acute syndrome with features resembling an acute coronary syndrome, with
left ventricular (LV) apical ballooning, that may occur
in association with LV outflow gradients that become
severe and unrelenting.1-3 Indeed, 30% of an unselected cohort of admitted patients with Takotsubo syndrome have typical phenotypic features of obstructive

HCM, including mild septal thickening, high outflow
gradients, elongated mitral leaflets, anterior position
of the valve, and anomalous anterior papillary muscles/shortened chordae.1 In these patients however,
obstructive HCM may be overlooked because of the
dramatic presentation, because the septal thickening
is mild (average, 15 mm),1,2 and because obstruction
may be latent. In this study, we report 14 patients with
HCM who developed cardiogenic shock because of
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this syndrome, whose treatment importantly differed
from other causes of shock. Diagnosis is key, as the
extent of permanent myocardial damage is diminutive
despite the extensive short-term decrease in ejection
fraction, and permits rapid return of normal LV systolic
function and normal hemodynamics when obstruction
is abolished.

METHODS
Data Sources
To appreciate this unique syndrome, we compiled information from our previously published reports in the
literature of 7 patients who presented to our 4 HCM
centers. One recent case that we cared for is described
herein for the first time without personal health information. We also summarized 6 relevant single case
reports from other authors reported in the literature.4-9
Because in the present article we review the previously
published data in 13 patients and there is no identifying patient information, our institutional review board
determined that this work did not meet the definition of
human subject research and therefore, approval was
not required. The materials used for this report will be
shared with researchers on request. Summary statistics are presented as mean±SD.
Downloaded from http://ahajournals.org by on December 14, 2021

RESULTS
Fourteen patients, aged 65.6±9 years, with 10 women
(71%), had hypotension at admission (systolic blood
pressure [BP], 74±9 mm Hg) and evidence of shock
and greatly reduced LV ejection fraction (25±5%).
Echocardiographic LV outflow peak gradient at rest
was 94±28 mm Hg. Septal thickness was 16±3 mm
(range, 12–20 mm). At angiography, no patient had significant coronary atherosclerotic stenosis (Tables S1
and S2).
All patients showed LV ballooning with akinesia or
dyskinesia of the apical-
mid segments with preservation of basal contraction. During the LV ballooning
event, there was marked mitral valve systolic anterior
motion (SAM) with mitral-septal contact. Severe mitral regurgitation attributable to SAM was present in
5 patients, whereas the other patients showed milder
degrees (Table S2). Figures 1 and 2 show multimodality imaging of a recent representative patient. ECG
abnormalities were as follows: ST-segment elevation
(n=7), ST depression or diffuse T-wave inversion (n=4),
or left bundle-branch block (n=2). Low-grade cardiac
biomarker elevations were noted in all.
One patient had survived a prior episode of apical ballooning. Inciting events to acute deterioration
included 7 patients with new-onset medical illness
(including 4 with new onset of atrial fibrillation as
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a contributing factor), 4 with emotional triggers, 1
after severe physical exertion, and 2 with no evident
trigger.
Details of treatment administered are shown in
the Table. Copious intravenous fluids were administered in 4 patients. There was no improvement from
conventional inotropic therapy with dopamine and
dobutamine. These agents were terminated in favor
of phenylephrine, norepinephrine, or vasopressin.
Intravenous β-blockade was administered to 7 patients
despite the low BP and low cardiac output state; in 6
patients, β-blockers were administered concomitantly
with phenylephrine to support BP. Pharmacotherapy
stabilized 6 (43%) patients, allowing weaning from vasoactive medications, with return of baseline systolic
LV function.
However, 8 patients required mechanical interventions, sometimes multiple: intra-
aortic balloon
counterpulsation (n=4), venoarterial extracorporeal membrane oxygenation (VA-ECMO) (n=3), and
Impella and Tandem Heart in 1 each. Failing these
measures, 5 patients had urgent surgical myectomy,
2 with concomitant mitral valve replacement because
maximal septal thickness was only 16 and 17 mm, respectively. One patient with multisystem failure, too ill
for myectomy, underwent alcohol septal ablation. All
patients survived their acute shock events; LV systolic function normalized hours to weeks after relief of
outflow obstruction. In 2 patients, there was marked
improvement in systolic function within 2 hours of
their operation. One additional patient with HCM
required myectomy for limiting symptoms 4 months
after his LV ballooning event.

DISCUSSION
The 14 patients with HCM analyzed herein developed cardiogenic shock attributable to high LV outflow peak gradients (average, 94 mm Hg) associated
with LV ballooning with apical and mid-LV wall motion
abnormality. These patients present with features resembling an acute coronary syndrome, but are found
to have normal coronary angiograms; as such, their
presentation mimics Takotsubo syndrome. However,
such patients with HCM have distinctive anatomic and
physiologic characteristics that set them apart from
the larger group of patients with Takotsubo syndrome
who have no outflow obstruction, normal mitral valves,
and normal septal thickness.1,2 Such distinction is important in both the short-term clinical phase because
of requirement for HCM-
specific treatment options
that differ from Takotsubo syndrome management and
long-term.
LV systolic dysfunction in patients with mild
septal thickening HCM is thought to be caused by
supply-d emand ischemia and afterload mismatch.
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Figure 1. A 58-
year-
old man with hypertrophic cardiomyopathy, mild resting gradients, and
provocable severe gradients, who subsequently developed severe persistent resting gradients,
left ventricular (LV) ballooning, and shock.
A, Before the ballooning event, an m-mode echocardiogram is shown at rest through the mitral valve tips,
showing systolic anterior motion (SAM) with transient mitral-septal contact (red arrows). B, Performed
after Valsalva shows prolonged mitral-
septal contact. Resting LV outflow gradient was 40 mm Hg,
increasing to 84 mm Hg after Valsalva. C, Systolic parasternal long-a xis view after Valsalva with SAM and
mitral-septal contact (red arrow). D, Cardiovascular magnetic resonance imaging diastolic 4-chamber
view with 17-mm anterior septal bulge (yellow arrow). E, Systolic frame. LV systolic function is normal. He
was treated with β-blockade and then, when intolerant of that, verapamil, with stable course.
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Figure 2. Same patient as Figure 1. Two years later, after 3 hours of physical labor, he developed resting chest discomfort,
hypotension (blood pressure, 78/50 mm Hg), pulmonary edema, new ST-segment elevation anteriorly, and an elevated
troponin I of 6 ng/mL.
His echocardiogram then showed the following: A, Diastolic apical 4-chamber view showing the ballooned apical and mid left
ventricular (LV) segments (arrowheads). There is mild asymmetric hypertrophy. Anterior mitral valve leaflet was elongated at 29 mm.
B, Systolic apical 4-chamber view showing mitral-septal contact and the ballooned dyskinetic and akinetic mid and apical segments
(arrowheads) with systolic anterior motion (SAM) of the mitral valve and mitral-septal contact (red arrow). The resting Doppler LV
outflow tract gradient was 135 mm Hg. C, Diastolic parasternal long-a xis view showing apical mid ballooning. D, Systolic parasternal
long-a xis view showing apical-mid ballooning and mitral-septal contact (red arrow). E, Severe, laterally directed mitral regurgitation
(yellow arrow). He was treated with intravenous (IV) metoprolol and IV phenylephrine. After 2 days of shock and persistent hypotension,
he could be weaned from parenteral therapy and was discharged on oral β-blocker. Echocardiogram performed 6 weeks later showed
hypertrophic cardiomyopathy (HCM), mild septal hypertrophy (13–14 mm), normal thickness of remaining segments, normal LV
systolic function, resting SAM, and gradient of 40 mm Hg. Over the ensuing months, he had limiting symptoms and higher resting
gradients with mitral regurgitation despite pharmacologic treatment, and thus was referred for extended surgical septal myectomy,
with improvement of symptoms. He is now New York Heart Association class II 4 months after surgery. Case demonstrates how
a patient with stable HCM and provocable obstruction with normal LV systolic function can suddenly develop unrelenting severe
obstruction, apical ballooning, severe LV systolic dysfunction, and cardiogenic shock.
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Table 1. Short-Term Treatment Received by 14 Patients With Cardiogenic Shock
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Four lines of evidence support this pathophysiology: (1) Severe LV outflow obstruction can cause
severe ischemia, documented by coronary vein
lactate production and nuclear and positron emission tomography techniques. Supply-
d emand
ischemia results from elevated LV systolic pressure and work, lowered diastolic BP with coronary
underperfusion, narrowed intramural coronaries,
and microvascular dysfunction. (2) Doppler evidence of inability to overcome afterload. With gradients ≥60 mm Hg, there is a ubiquitous reversible
midsystolic decrease in LV pulsed Doppler ejection velocities and flow10 attributable to premature
termination of segmental contraction.11 This is an
afterload mismatch phenomena, first observed
in patients with obstructive HCM 24 years ago,10
collectively termed “paradoxical reversible systolic
dysfunction.” Systolic impairment is paradoxical
because HCM is understood as a hyperdynamic
condition. This is evidence of instantaneous systolic heart failure attributable to afterload. We
believe that ballooning in HCM is a more severe
manifestation of dynamic systolic dysfunction attributable to sudden outflow obstruction. (3) We
have not observed LV ballooning in our patients
with nonobstructive HCM, nor, to our knowledge,
has it been reported in the literature. This underscores the causative importance of high gradients
in ballooning. (4) The rapid resolution of refractory
shock and severe LV systolic dysfunction after septal reduction in 6 of our patients is compelling evidence that obstruction causes the LV dysfunction.
Two patients had rapid improvement in LV function
within 2 hours of surgery.3
In apical ballooning, it has been proposed that outflow obstruction results from a narrowed hyperkinetic
outflow tract, with development of Venturi forces there,
attributable to functional alteration of LV geometry.
However, the weight of evidence about SAM in HCM
is that it is caused by flow drag, the pushing force of
flow, and not by a Venturi effect. Outflow velocities are
low in obstructive HCM when SAM begins, precluding Venturi forces as a mechanism.12,13 In patients with
obstructed HCM with apical ballooning, we propose
that mitral-septal contact is not a result of wall motion
abnormalities, but instead may be their cause.1-3
We previously reported that an episode of acute
apical ballooning occurred in about 1% of patients in
our prospectively acquired database of patients with
HCM.2 Of those with ballooning, cardiogenic shock
occurred in a third. A common denominator of the patients with obstructive HCM with ballooning has been
relatively mild septal thickening, about 15 mm, less
than in our other patients with HCM, 20 mm,1,2 and
now, in patients with obstructive HCM with shock,
where septal thickness was 16 mm. We hypothesize
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that in the typical patient with HCM, severe hypertrophy acts as a buttress to prevent the development
of ballooning. In contrast, in patients with ballooning,
mildly thickened walls may be unprepared to perform
in the face of high LV pressures, and extremely high
wall stress. (Wall thickness is in the denominator of the
wall stress equation.)
In obstructive HCM, mitral regurgitation is caused
by SAM and dynamic deformation of the mitral valve.
Of the 14 patients, 5 had severe mitral regurgitation
associated with outflow gradients that undoubtedly
contributed to their low stroke volume and shock.

Therapy
Because LV outflow gradients are the cause of the
acute deterioration, therapy is targeted to abolish
SAM and mitral-septal contact. Initial measures designed to reverse provoking causes are administered:
intravenous fluids for volume depletion, blood transfusion for anemia, and urgent cardioversion for rapid
atrial fibrillation. The mainstay of therapy of patients
with HCM with apical ballooning, but without hemodynamic instability, is β-blocker therapy, administered
intravenously.2 Although it may seem counterintuitive to treat with β-blockers when BP is borderline
or low, nevertheless in our experience, LV outflow
gradients often decrease, and BP either increases or
remains unchanged. We typically administer intravenous metoprolol, 15 mg, over 15 minutes with careful
monitoring of BP and heart rate. We have found such
therapy to be safe in this scenario. Esmolol infusion is
an alternative; however, titration may require time. We
therefore prefer metoprolol. However, when hypotension and poor tissue perfusion are evident, pharmacologic choices become limited. We are reticent to
administer metoprolol alone to patients with systolic
BP <80 mm Hg; when this occurs, the combination
of phenylephrine to support BP along with metoprolol is preferred.
Positive inotropic agents, such as dopamine, dobutamine, and milrinone, should be explicitly avoided
because the drugs worsen dynamic obstruction and
exacerbate shock. Six of our patients could be successfully managed by reversing outflow obstruction
with pharmacotherapy, whereas the majority required
advanced invasive therapy.

Mechanical Circulatory Support
The differences between methods of invasive circulatory support have previously been described. Although
intra-
aortic balloon counterpulsation improves coronary perfusion during diastole, the presystolic deflation
decreases afterload and may thus worsen, or produce
de novo LV outflow obstruction. The Impella catheter delivers blood into the proximal aorta, decreases
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preload, and offers partial LV support. However, decreasing LV cavity size in HCM may promote SAM and
increase LV outflow obstruction. The same phenomenon may occur with the Tandem Heart. In contrast,
VA-ECMO increases afterload by retrograde flow, while
augmenting cardiac output and coronary perfusion.
Obstructive HCM physiology generally responds well
to mildly increased afterload. VA-ECMO offers full circulatory support for the sickest patients, and can be
initiated rapidly at the bedside.
Of the 14 patients, intra-aortic balloon counterpulsation was used in 4 and may have aided recovery in
2, but failed to improve shock in the other 2. VA-ECMO
stabilized BP in 3 patients who were supported for 4
to 13 days; its use has been successful in 2 other prior
reports of shock attributable to LV outflow obstruction. When it is locally available, VA-ECMO may be the
best choice for temporary circulatory support, to allow
the LV to recover, or as a bridge to septal reduction
therapy. Weaning should be tried after stabilization.
However, when tapering from VA-ECMO cannot be
achieved, because of recurrent obstruction, septal
reduction is the next step. Durable LV assist devices
have been used successfully in patients with HCM as
a bridge to transplantation, although small chamber
sizes and LV muscle bundles can impede the inflow
cannula. We do not advocate for durable LV assist
device use herein because relatively rapid, complete
reversal of abnormal systolic function is expected on
abolition of outflow obstruction.

Septal Myectomy
Surgical relief of LV outflow obstruction is the definitive therapy to immediately and permanently abolish LV outflow gradient, and to reduce afterload and
supply-demand ischemia. Of the 14 patients, 5 required urgent surgical myectomy, 2 with concomitant mitral valve replacement in 2007. In the current
era, these 2 patients, with septal thicknesses of 16
and 17 mm, respectively, would not have mitral valve
replacement; rather, with refined surgical techniques
developed since then, shallow but extended myectomy would be performed with consideration of ancillary mitral valve repair (ie, mitral shortening for an
elongated anterior leaflet or chordal cutting when
these structures position the mitral valve in the flow
stream). However, in that era of ≈2007, mitral valve
replacement was the norm for patients with thin septum. In that era, at that time, our judgement was to
definitively abolish LV outflow obstruction without the
potential need for a second pump run that the patient
might not survive. In making these judgements in critically ill patients, the risk of "undertreating" is greater
than that of "overtreating.” One additional patient required surgical myectomy for limiting symptoms and
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gradient 4 months after recovery from the LV ballooning event.
One patient had “bail-out” alcohol septal ablation
performed because multisystem failure precluded
myectomy. Because alcohol ablation causes a septal
infarct, there is the potential for exacerbating hemodynamic instability. Also, surgery provides immediate and reliable relief of obstruction, compared with
ablation, which may require weeks for effect. For
these reasons, we recommend surgery over alcohol
ablation. The institution of cardiopulmonary bypass
itself can reverse the ischemic process. Indeed, in
2 patients, after the bypass run and abolishing outflow obstruction, we observed improvement in LV
function almost immediately.3 Although there is understandable reticence to operate on patients with
acute myocardial ischemia, cardiogenic shock, and
systemic acidosis, when pharmacotherapy fails to
reverse shock, surgical intervention is necessary.
Indeed, this clinical scenario is one of the few in
HCM requiring emergent surgical intervention. When
LV outflow gradients cause obstruction and ballooning, the patients with HCM may be confused with the
larger group of patients with non-HCM Takotsubo
syndrome. In this clinical scenario, decisions must
be made in hours, often in the emergency department, and misdiagnosis of the true pathophysiology
can result in fatal missteps, underscoring the need
for a prepared team. Familiarity with the many anatomic variants found in HCM, particularly of the mitral
valve, can speed recognition. Figure S1 summarizes
our recommended approach for these critically ill
patients.
We acknowledge the possibility of publication bias;
patients who do not do well may not be the subject of
case reports, and patients who have succumbed from
this syndrome may not have come to our attention. We
also acknowledge that natural history of LV ballooning
syndrome often results in spontaneous and complete
resolution. We believe this would not have been the
case for our patients who required mechanical support
and septal reduction who were in extremis before their
interventions.

CONCLUSIONS
When shock occurs in obstructive HCM with LV
ballooning, therapy targeted to reduce or abolish
obstruction may lead to survival with complete recovery of LV systolic function. Reversing provoking factors, like dehydration, anemia, and atrial
fibrillation, should be instituted first. Pharmacologic
therapy with β-blockade and vasoconstrictor medication may reverse outflow obstruction and shock.
However, if initial measures do not improve shock
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or if the patient cannot be weaned from intravenous
therapy, circulatory support with VA-ECMO or other
modalities should be promptly instituted. If mechanical support cannot be discontinued, and high gradients persist, surgical relief of obstruction should be
undertaken urgently.
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Figure S1. Treatment paradigm for obstructive HCM with LV ballooning and cardiogenic shock
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Table S1. Clinical characteristics of 14 Obstructive HCM Patients with Cardiogenic Shock and Acute
LV Ballooning
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Author

Sex Age

Precipitant

ECG

Trop I
ng/ml
CPK (U/dl)

Shock
Pedema
BP
(mmHg)

Sherrid 2011 3

M

70

Gastroenteritis
with diarrhea

Trop I 1.2

77/42

+

Sherrid 2011 3

M

52

None

NM

80/50

0

Sherrid 2019 2

F

63

gastroenteritis

Trop I 2.4

80/60

0

Sherrid 2019 2

F

66

Delivered eulogy

LVH with more ST
depressions
laterally
Diffuse ST
depressions;
enzyme
elevations.
ST elevation and
Q waves
anteriorly
ST depression
and TWI

Trop I 1.4

82/59

+

Sherrid 2019 2

F

61

None

Trop I 2.72

83/61

0

Husaini 2020 4

F

68

Trop T 0.46 83/59

+

Caniato 2021 5

M

49

Husband's
severe illness
pulmonary
infection, atrial
fibrillation

LVH, ST elev 1,
AvL
LBBB
Repolarization
abnormalities

80/50

+

*Wever-Pinzon, Fig
1,2

M

58

Exhaustion p 3
hrs labor

Anterior ST
elevations

hsTnT 165
pg/mL;
CK-MB
7.2mcg/L
Trop 6

78/50

+

Yasutoni 1989 11 †

F

63

58/

0

F

69

ST elevation and
TWI 2,3,AvF,V2V6;
Afib, LBBB with
LAD

CPK 257
MB 9%.

Cevik 2018 6 †

Uterine CA
chemo,
dehydration
New onset Afib

NM

70/50

+

Arakawa 2018 7 †

F

62

Severe emotional ST elevation I,
stress
aVL, V3-V6

Trop I 1.53

0

Nalluri 2018 8 †

F

81

GI bleeding,
anemia, Afib

Precordial TWI

Trop I 1.26

78/50
to
48/24
60/40

Sosalla 2019 9 †

F

78

Extreme weather

NM

Trop
elevated

NM

-

Sato 2020 10 †

F

81

Influenza; afib

Anterior ST
elevation with
loss of R waves

Trop I 8.86
CKMB 11

132/96
to
74/40

0

+

*Patient reported here for the first time. † Six cases reported by other authors.
Coro Sten=coronary stenosis; hsTnT=high sensitivity troponin T; NM=not mentioned in case report;
pedema=pulmonary edema; Trop=troponin; TWI=T wave inversion

Table S2. Acute echocardiographic findings in 14 patients with shock
Author

Septal
thick
(mm)
17

MR
(04);
2

Mitral
morphology

Sherrid 2011 3

LVOT
LVEF(%)
gradient
(mmHg)
90
25

Sherrid 2011 3

135

25

16

2

Anom PM

Sherrid 2019 2

60

30

14

4

Sherrid 2019 2

80

25

13

4

Elong leaf;
Anom PM
Elong leaf

Sherrid 2019 2

100

25

12

NM

NM

Husaini 2020 4

46
initially
and
then
severe
90

30

19

1

Elong leaf

15

18

3-4

Elong leaf

*WeverPinzon, Fig 1,2

135

30

19

3-4

Elong leaf

Yasutoni 1989 11

120

NM

20

NM

-

Cevik 2018 6 †

>50
20
"severe"
59
NM

NM

NM

-

4

-

4

-

4

-

Caniato 2021 5

Downloaded from http://ahajournals.org by on December 14, 2021

†

Arakawa 2018 7

Nalluri 2018 8 †

>90

20-25

mild
basal
bulge
ASH

Sosalla 2019 9 †

120

30

16-17

107

NM

†

Elong leaf

mild
3
basal
bulge
*Patient reported here for the first time. † Six cases reported by other authors.
Anom PM=anomalous papillary muscle; Elong leaf=Elongated mitral leaflet(s);
NM=not mentioned in case report
Sato 2020 10 †
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